NCT01144897

PET Acetate for Castrate-Resistant Prostate Cancer on Chemotherapy

PET Acetate for Docetaxel Response Assessment in Hormone-Refractory Prostate Cancer

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Daniel Vaena · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

One purpose of this research study is to examine if a special type of imaging test, a positron emission tomography (PET) scan using the radioactive material \[C-11\] acetate, will be helpful in detecting prostate cancer lesions in subjects with castrate-resistant prostate cancer (CRPC). This PET scan will be combined with a computed tomography (CT) scan taken during the same imaging session. The other purpose of the PET-CT scan using \[C-11\] acetate (PET Acetate Scan) is to assist in identifying who is responding to the treatment (docetaxel chemotherapy).

Detailed description

The purpose of the current pilot clinical trial is to attempt to identify the safety and accuracy of PET-acetate imaging in the assessment of response of persons undergoing first-line docetaxel for CRPC. If successful, the current research could lead to the incorporation of PET-acetate into future study protocols where continuation of chemotherapy is based on early PET-acetate results, provided that effective second-line therapy options are available (which is an expectation for the near future, based on several ongoing and presented phase III trials).

Conditions

• Castrate Resistant Prostate Cancer
• Prostate Cancer

Interventions

Type	Name	Description
RADIATION	PET Acetate scan	PET Acetate scans will be done to detect prostate cancer lesions.
DRUG	Carbon-11 labeled Acetate	C-11 Acetate is a radiotracer used in PET scanning

Timeline

• Start date: 2010-05-01
• Primary completion: 2011-11-01
• Completion: 2018-09-01
• First posted: 2010-06-16
• Last updated: 2018-10-02

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study